NEW YORK (GenomeWeb) – Epigenomics today said it raised $5.3 million to finance current operations and to expand distribution of its Epi proColon colorectal cancer test.

The funds were raised through a subscription by clinical diagnostics firm BioChain Institute of about 1.35 million shares of Epigenomics stock. Epigenomics issued the new shares at €3.08 ($3.95) per share. After the capital increase is registered, expected on or about Nov. 21, Epigenomics' subscribed capital will increase to €14.9 million from €13.5 million currently, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.